These emerging therapies , Tirzepatide , represent a significant advancement in addressing metabolic dysfunction and conceivably associated disorders. They all are classified as GLP-1 receptor agonists https://ammarrdap579112.post-blogs.com/62260933/semaglutide-a-deep-exploration-into-metabolic-compounds